Measurable residual disease including AML leukemia stem cell flow evaluation of CPX-351 therapy by multi-parameter flow cytometry

Leuk Res. 2021 Dec:111:106673. doi: 10.1016/j.leukres.2021.106673. Epub 2021 Jul 26.

Authors

Adriana Plesa¹, Christophe Roumier², Joris Gutrin¹, Marie-Virginie Larcher³, Marie Balsat³, Octavia Cadassou¹, Fiorenza Barraco³, Gaëlle Fossard³, Amandine Baudouin⁴, Hélène Labussière³, Isabelle Tigaud¹, Sophie Ducastelle³, Sandrine Hayette¹, Pierre Sujobert¹, Maël Heiblig³, Mohamed Elhamri³, Xavier Thomas⁵

Affiliations

¹ Hospices Civils de Lyon, Lyon-Sud Hospital, Hematology Laboratory, Pierre-Bénite, France.
² Centre Hospitalier Régional Universitaire de Lille, Hematology Laboratory, Lille, France.
³ Hospices Civils de Lyon, Lyon-Sud Hospital, Clinical Hematology, Pierre-Bénite, France.
⁴ Hospices Civils de Lyon, Lyon-Sud Hospital, Hospital Pharmacy, Pierre-Bénite, France.
⁵ Hospices Civils de Lyon, Lyon-Sud Hospital, Clinical Hematology, Pierre-Bénite, France. Electronic address: [email protected].

PMID: 34364023
DOI: 10.1016/j.leukres.2021.106673

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Biomarkers, Tumor / analysis
Biomarkers, Tumor / metabolism*
Cytarabine / therapeutic use*
Daunorubicin / therapeutic use*
Female
Follow-Up Studies
Humans
Leukemia, Myeloid, Acute / drug therapy
Leukemia, Myeloid, Acute / metabolism
Leukemia, Myeloid, Acute / pathology*
Male
Middle Aged
Neoplasm Recurrence, Local / drug therapy
Neoplasm Recurrence, Local / metabolism
Neoplasm Recurrence, Local / pathology*
Neoplasm, Residual / drug therapy
Neoplasm, Residual / metabolism
Neoplasm, Residual / pathology*
Neoplastic Stem Cells / drug effects
Neoplastic Stem Cells / metabolism
Neoplastic Stem Cells / pathology*
Prognosis
Retrospective Studies
Young Adult

Substances

Biomarkers, Tumor
CPX-351
Cytarabine
Daunorubicin